These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6273502)

  • 1. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans.
    Kew OM; Nottay BK; Hatch MH; Nakano JH; Obijeski JF
    J Gen Virol; 1981 Oct; 56(Pt 2):337-47. PubMed ID: 6273502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients.
    Yoneyama T; Hagiwara A; Hara M; Shimojo H
    Infect Immun; 1982 Jul; 37(1):46-53. PubMed ID: 6179881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative biochemical studies of type 3 poliovirus.
    Minor PD
    J Virol; 1980 Apr; 34(1):73-84. PubMed ID: 6246264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic and biochemical characterization of poliovirus type 1 isolates of non-vaccine origin.
    Hara M; Hagiwara A; Yoneyama T; Saito Y; Shimojo H
    Microbiol Immunol; 1983; 27(12):1057-65. PubMed ID: 6328228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of strains of type 3 poliovirus by oligonucleotide mapping.
    Minor PD
    J Gen Virol; 1982 Apr; 59(Pt 2):307-17. PubMed ID: 6281371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics of the genome of poliovirus type 3 isolated from patients with poliomyelitis in Moldavia].
    Lipskaia GIu; Seĭbil' VB; Malyshkina LP; Gidirim VN; Drozdov SG
    Mol Gen Mikrobiol Virusol; 1985 Sep; (9):27-32. PubMed ID: 3025721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Isolation of recombinant vaccine strains of poliovirus from patients with poliomyelitis].
    Kutitova OK; Lipskaia GIu; Maslova SV; Agol VI
    Mol Gen Mikrobiol Virusol; 1989 Nov; (11):14-20. PubMed ID: 2560812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees.
    Tatem JM; Weeks-Levy C; Mento SJ; DiMichele SJ; Georgiu A; Waterfield WF; Sheip B; Costalas C; Davies T; Ritchey MB
    J Med Virol; 1991 Oct; 35(2):101-9. PubMed ID: 1662701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The nature of virus strains isolated from patients with poliomyelitis in the Byelorussian SSR 1967-1985].
    Lipskaia GIu; Kutitova OK; Fel'dman EV; Votiakov VI; Maslova SV
    Mol Gen Mikrobiol Virusol; 1987 Oct; (10):30-7. PubMed ID: 2448613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary.
    Kapusinszky B; Molnár Z; Szomor KN; Berencsi G
    FEMS Immunol Med Microbiol; 2010 Mar; 58(2):211-7. PubMed ID: 19863665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans.
    Friedrich F
    Acta Virol; 1998 Jun; 42(3):187-94. PubMed ID: 9842449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic and biochemical characterization of poliovirus type 2 isolated from two cases of paralytic disease.
    Fiore L; Pierangeli A; Lombardi F; Santoro R; Crainic R; Venuti A; Perez-Bercoff R
    Intervirology; 1987; 27(4):196-204. PubMed ID: 2447031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine-associated cases of poliomyelitis over a 30 year period in East Germany.
    Driesel G; Diedrich S; Kunkel U; Schreier E
    Eur J Epidemiol; 1995 Dec; 11(6):647-54. PubMed ID: 8861848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paralytic poliomyelitis in Norway since the introduction of trivalent oral vaccine: an epidemiological and virological study.
    Orstavik I; Flugsrud LB; Lahelle O
    Bull World Health Organ; 1971; 45(6):733-9. PubMed ID: 4336552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses.
    Otelea D; Guillot S; Furione M; Combiescu AA; Balanant J; Candrea A; Crainic R
    Dev Biol Stand; 1993; 78():33-8. PubMed ID: 8099049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases.
    Lipskaya GY; Muzychenko AR; Kutitova OK; Maslova SV; Equestre M; Drozdov SG; Bercoff RP; Agol VI
    J Med Virol; 1991 Dec; 35(4):290-6. PubMed ID: 1666406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans.
    Nottay BK; Kew OM; Hatch MH; Heyward JT; Obijeski JF
    Virology; 1981 Jan; 108(2):405-23. PubMed ID: 6258294
    [No Abstract]   [Full Text] [Related]  

  • 18. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus.
    Kew O; Morris-Glasgow V; Landaverde M; Burns C; Shaw J; Garib Z; André J; Blackman E; Freeman CJ; Jorba J; Sutter R; Tambini G; Venczel L; Pedreira C; Laender F; Shimizu H; Yoneyama T; Miyamura T; van Der Avoort H; Oberste MS; Kilpatrick D; Cochi S; Pallansch M; de Quadros C
    Science; 2002 Apr; 296(5566):356-9. PubMed ID: 11896235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurovirulence of the intertypic poliovirus recombinant v3/a1-25: characterization of strains isolated from the spinal cord of diseased monkeys and evaluation of the contribution of the 3' half of the genome.
    Agol VI; Drozdov SG; Frolova MP; Grachev VP; Kolesnikova MS; Kozlov VG; Ralph NM; Romanova LI; Tolskaya EA; Viktorova EG
    J Gen Virol; 1985 Feb; 66 ( Pt 2)():309-16. PubMed ID: 2981970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis.
    Strebel PM; Ion-Nedelcu N; Baughman AL; Sutter RW; Cochi SL
    N Engl J Med; 1995 Feb; 332(8):500-6. PubMed ID: 7830731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.